Deep Medicine Acquisition Corp. Announces Appointment of a New Director
24 Octubre 2022 - 4:35PM
Deep Medicine Acquisition Corp. (Nasdaq: DMAQ) (the “Company”)
announced today the appointment of Mr. John Chiang as a member to
its board of directors, effective October 15, 2022.
Mr. Chiang has been serving as a member of the
board of directors of Apollo Medical Holdings, Inc. since January
2019 and on the corporate advisory boards of Pasadena Private
Lending, LLC since February 2019, Adept Urban since January 2021,
and Calyx Peak Companies since February 2019. From January 2015 to
January 2019, Mr. Chiang served as the California State Treasurer,
where he oversaw financial transactions, investments and the sale
of bonds. Prior to that, Mr. Chiang served as California State
Controller from January 2007 to January 2015.
Humphrey Polanen, Chairman of the board of
directors and the Company’s Chief Executive Officer, on behalf of
the board of directors and management, said, "The DMAQ board of
directors is delighted that John has chosen to contribute his
expertise and wide ranging experience as a statewide elected
official to our company. As a former State of California Controller
and Treasurer, John Chiang has a unique background that will
strengthen our board.”
About Deep Medicine
Acquisition Corp.
DMAQ is a special purpose acquisition company
formed for the purpose of entering into a merger, capital stock
exchange, asset acquisition, stock purchase, reorganization or
other similar business combination with one or more businesses or
entities. DMAQ began trading on the Nasdaq in October 2021, and its
common stock and rights are traded under the ticker symbols DMAQ
and DMAQR, respectively.
Cautionary Note Regarding
Forward-Looking Statements
This press release may include, and oral
statements made from time to time by representatives of the Company
may include, “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. Statements
regarding possible business combinations and the financing thereof,
and related matters, as well as all other statements other than
statements of historical fact included in this press release are
forward-looking statements. When used in this press release, words
such as “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions, as they relate to us or our management team, identify
forward-looking statements. Such forward-looking statements are
based on the beliefs of management, as well as assumptions made by,
and information currently available to, the Company’s management.
Actual results could differ materially from those contemplated by
the forward-looking statements as a result of certain factors
detailed in the Company’s filings with the Securities and Exchange
Commission (“SEC”). All subsequent written or oral forward-looking
statements attributable to us or persons acting on our behalf are
qualified in their entirety by this paragraph. Forward-looking
statements are subject to numerous conditions, many of which are
beyond the control of the Company, including those set forth in the
Risk Factors section of the Company’s registration statement and
prospectus for the Company’s initial public offering filed with the
SEC. The Company undertakes no obligation to update these
statements for revisions or changes after the date of this release,
except as required by law.
Contact
Humphrey Polanen, Chief Executive Officer
Deep Medicine Acquisition Corp.
595 Madison Avenue, 12th Floor
New York, NY 10017
ir@dmaq-spac.com
Telephone: (917) 289-2776
Deep Medicine Acquisition (NASDAQ:DMAQ)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Deep Medicine Acquisition (NASDAQ:DMAQ)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024